Sylvain Fanier

President, Atonco

ATO-101™: A THERAPEUTIC ADVANCE FOR THE TREATMENT OF NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)

ABSTRACT

Non-muscle-invasive bladder cancer (NMIBC) presents a significant medical challenge, with a growing need for novel therapeutic options. Atonco develops a promising approach in the area of alpha-immunotherapy treatment using its first radiopharmaceutical, ATO-101 ([211At]At-girentuximab), a CA-IX antigen radiolabeled with astatine-211. The goal of Atonco’s is to assess the potential of ATO-101™ in treating patients who do not respond to conventional bladder cancer treatments.

Atonco’s preclinical and clinical study results have been published in the Cancers (MDPI) journal in March 2025, highlighting the promising potential of its ATO-101™ in the using astatine-211 of non-muscle-invasive bladder cancer (NMIBC) refractory to standard therapies, including BCG.

SPEAKER BIO

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Return to conference agenda